Please login to the form below

Not currently logged in
Email:
Password:

Storm Therapeutics bolsters its team

Professor Mark Dawson and Dr Paul Leeson join its scientific advisory board

UK-based drug discovery group Storm Therapeutics has strengthened its scientific advisory board with the addition of Professor Mark Dawson.

As a clinician-scientist at the University of Melbourne, Professor Dawson has experience in epigenetics having spent several years researching epigenetic regulation of leukaemia stem cells.

Dr Paul Leeson also joins the University of Cambridge spin-out, following 35 years’ experience of drug discovery and development in senior roles in pharmaceutical companies including GlaxoSmithKline, Merck Sharp and Dohme and AstraZeneca.

Keith Blundy, chief executive officer of Storm Therapeutics, said: “Mark’s expertise in epigenetics research will be invaluable as we advance selected targets into drug discovery, along with Paul’s long standing experience in drug discovery and development at big pharma will help Storm maximise the potential of our pipeline and harness the power of RNA epigenetics as a new area of important biology.”

3rd January 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics